ArticleCureus2025
Complete Remission of Plasmablastic Lymphoma With Daratumumab and a Mild Regimen of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (Mini-CHOP).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of diffuse large B-cell lymphoma, characterized by a dismal prognosis. Due to its rarity and aggressive nature, no established standard of care exists for PBL. Treatment is primarily based on large B-cell lymphoma- or multiple myeloma-based chemotherapy regimens, and outcomes remain poor. We present an 84-year-old man with an extensive oncologic history who presented with PBL on his right foot which did not respond to subsequent radiation treatment. A mild regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (mini-CHOP) normally utilized to treat large B-cell lymphoma was supplemented with the CD38-directed monoclonal antibody, daratumumab. This combination regimen was selected for the elderly patient due to his weakened condition. Upon six cycles of daratumumab-mini-CHOP, the patient achieved complete remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.